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Abstract: Nanocrystalline materials (NCM, i.e., crystalline nanoparticles) have become an important
class of materials with great potential for applications ranging from drug delivery and electronics to
optics. Drug nanocrystals (NC) and nano co-crystals (NCC) are examples of NCM with fascinating
physicochemical properties and have attracted significant attention in drug delivery. NCM are cate-
gorized by advantageous properties, such as high drug-loading efficiency, good long-term physical
stability, steady and predictable drug release, and long systemic circulation time. These properties
make them excellent formulations for the efficient delivery of a variety of active pharmaceutical
ingredients (API). In this review, we summarize the recent advances in drug NCM-based therapy
options. Currently, there are three main methods to synthesize drug NCM, including top-down,
bottom-up, and combination methods. The fundamental characterization methods of drug NCM are
elaborated. Furthermore, the applications of these characterizations and their implications on the
post-formulation performance of NCM are introduced.
Keywords: nanocrystalline materials; physicochemical characterization; vibrational spectroscopy;
X-ray analysis; thermal analysis; critical quality attributes
1. Introduction
There has been an increasing interest in developing drug delivery systems that cir-
cumvent the challenges associated with conventional drug delivery [1]. Among those
challenges are poor drug solubility and formulation stability, low bioavailability, and
undesirable side effect profiles [1]. Solutions to some of these shortcomings have been
suggested and have included the use of nanotechnology. Nanotechnology is defined as
the engineering and manufacture of materials at an atomic or molecular scale resulting in
nanoparticles [2]. The definition of nanoparticles regarding particle size is constantly under
deliberation. This has resulted in different disciplines adopting different definitions. As an
example, colloid chemistry describes nanoparticles as having particle sizes below 100 nm
or and in some instances 20 nm. In the pharmaceutical domain, nanoparticles are identified
as having a size ≤ 1000 nm [3]. Therefore, in this review, we define nanocrystalline (NCM)
as crystalline materials composed of nanoparticles having dimensions <1000 nm [4,5].
Some of the desirable properties of nanoparticles are that they often maintain crystallinity
after their manufacturing process. Crystallinity relates to the extent of structural order
in a solid and is characterized by atomic or molecular arrangement being regular and
periodic—the production of nanoparticles that exhibit crystallinity results in the forma-
tion of NCM. The production of NCM requires a combination of crystal engineering and
nanotechnological approaches.
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Crystal engineering is the manipulation of non-covalent interactions between molecu-
lar or ionic components for the rational design of solid-state structures that may exhibit
desirable electrical, magnetic, and optical properties [6]. Intermolecular hydrogen bonds
can be used to assemble supramolecular structures that, at the very minimum, control or
influence dimensionality [6,7]. Crystal engineering can also be described as the knowl-
edge of intermolecular interactions in the context of crystal packing and the use of such
understanding in the design of new solid materials with desirable physicochemical proper-
ties [8,9].
Co-crystals are single-phase crystalline solids that are composed of two or more
different molecular or ionic compounds, generally in a stoichiometric ratio [10]. Co-crystals
can be constructed using several types of molecular interactions such as hydrogen bonds,
ionic interactions, π–π stacking, and van der Waal’s forces [11–14].
Two general methods are used to manufacture NCM. The first utilizes collision forces
to cause particle size reduction to nanometer dimensions and is called the top-down
approach [15,16], while the second approach makes use of nucleation and crystal growth.
A suitable stabilizer is utilized to prevent crystal growth into the micrometre range and
is termed the bottom-up approach [17,18]. In the broadest sense, NCM used in drug
delivery can be subdivided into organic and inorganic NCM. In this review, we focus on
the characterization of organic NCM for the delivery of active pharmaceutical ingredients
(API). More specifically, we highlight the characterization techniques most applicable to
NC and NCC as models NCM for the delivery of API.
Drug NC are crystals with a size in the nanometre range. This means that they
are nanoparticles that exhibit a high degree of crystallinity [3]. Similarly, drug NCC are
crystalline solids existing as a single phase that is composed of different molecules that have
nanometric dimensions [19]. In the case of both types of the aforementioned NCM, crystal
growth from the nanometer to the micrometre range is inhibited by stabilizers [20–22].
In drug delivery, these NCM have found a broad range of applications in circumvent-
ing the shortcomings of conventional drug delivery while exhibiting flexibility regarding
the routes of administration.
When applied in transdermal delivery, NCM are expected to pack tightly and form
a dense layer that hydrates the skin and improves drug penetration and permeation.
Dissolved NCM may be topically retained for a sufficient period and offer sustained API
release [23]. As a way of example, a formulation of L-ascorbic acid demonstrated long-
term stability as NC dispersed in an oil base. The NC oil dispersion exhibited improved
penetration and stability when compared to conventional technologies [24].
Oral administration remains the most preferred route and is generally considered a
safe and suitable drug delivery route [25]. Dissolution is often the rate-determining step
for absorption, and because NCM generally provide a larger surface area for dissolution,
increase saturation solubility, and ultimately increase the dissolution extent, they have been
shown to enhance API absorption [26]. Rapamune®, a formulation composed of sirolimus
NC blended with additional excipients and directly compressed into tablets, was the
first US FDA-approved nanocrystalline drug launched in 2000 by Wyeth Pharmaceuticals
(Madison, NJ, USA) for oral use. The oral bioavailability of the API from the nanocrystalline
tablets was 21% higher than that of sirolimus delivered in aqueous solution [27]. Similarly,
the advantages of nano-drug delivery have been applied to modulate the pharmacokinetic
profile of aprepitant (Emend®), which requires delivery at an absorption window in the
gastrointestinal tract [28].
Drug delivery to the eye is hindered by pharmacokinetic, physiological, and in some
instance’s environmental factors. Conventional formulations are rapidly cleared from the
site of administration due to rapid eye movement such as blinking and/or lacrimation,
resulting in low ocular bioavailability. Consequently, repeated dosing and subsequent
reduction in adherence results in poor clinical outcomes. Frequent dosing may also lead to
an increase in dose-dependent side effects [29,30]. NCM technologies can play a critical
role in drug delivery to the eye by improving the solubility of poorly soluble API. This was
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explored and showed favourable outcomes when utilized in formulations containing budes-
onide, dexamethasone, hydrocortisone, prednisolone [31], and fluorometholone [31,32].
A technique based on combining microfluidic and milling technologies resulted in the
production of NC of hydrocortisone. The ocular bioavailability of the NC was evaluated
in vivo using albino rabbits. Extended duration of action and a significant improvement in
the area under the curve (AUC) for hydrocortisone delivered using the NC were observed
when compared to coarse hydrocortisone [33].
Parenteral drug delivery ensures a shorter onset of action, higher bioavailability, and
use of reduced doses when compared to oral drug delivery. These benefits are ideal target
parameters for drug delivery; however, the use of the intravenous route is challenging as
only a limited number of solvents and excipients can be used during formulation devel-
opment. This is due to an increased possibility of adverse outcomes in addition to those
caused by the API. NC of ascularine [34], melarsoprol [35], oridonin [36], itraconazole [37],
and curcumin [38] have been successfully developed and resulted in increases in their Cmax
and AUC0–∞.
Targeted delivery approaches have been implemented in combination with NC and
NCC technology for drugs that exhibit low bioavailability, poor aqueous solubility and
stability, and limited in vitro–in vivo correlations (IVIVC) [39,40]. Buparvaquone NC
suspended in a mucoadhesive system of Carbopol® 934, 971, 974, 980 or 0.5 % w/w
Noveon® AA-1 was used for targeting the gastrointestinal parasite, Cryptosporidium parvum,
and resulted in better targeting and greater stability than pure buparvaquone [41].
Surface modification of NCM can also be used to reduce the potential toxicity of API
to selected cell lines. For instance, surface modification of lamivudine-zidovudine NCC
with sodium dodecyl sulphate (SDS) and α-tocopheryl polyethylene glycol succinate 1000
(TPGS 1000) was reported to have reduced cytotoxic effect on HeLa cells [42].
Despite their success in drug delivery, NCM have to undergo rigorous characteriza-
tion prior to their use in humans. Many of these techniques are centred on developing
quality into the product and ensuring that critical process parameters (CPP) do not have a
significant impact on the critical quality attributes (CQA) of the product [43]. Consequently,
the resultant NC or NCC meets the quality target product profile (QTPP) that could lead to
inclusion into suitable dosage forms and subsequent human use.
Formulation and morphology of drug NCM, including fundamental characterizations
and their implications on post-formulation performance are described below.
2. Formulation and Morphology of NCM
Two formulation approaches have been shown to produce NC viz., the top-down tech-
nique that relies on shear forces for particle size reduction into the nanometre range [15,16]
and the bottom-up approach that allows for nucleation and growth of individual monomers,
which remain nanosized because of a stabiliser [17,18].
2.1. Top-Down Production Approaches
High-energy mechanical forces are involved in top-down approaches and are pro-
vided by media milling (MM) techniques, including NanoCrystals® or high-pressure
homogenization (HPH), Insoluble Drug Delivery—Particles (IDD-P™), DissoCubes®, and
Nanopure®, to comminute large crystals into crystals of smaller dimensions [16,44]. Top-
down processes are commonly used for the preparation of crystalline nanoparticles [45]
and are flexible following scale-up production [46]. Consequently, the process has been
widely adopted for commercial scale preparation of nanocrystals. With the exception
of Triglides produced by IDD-P®, the majority of the other products are commercially
produced using NanoCrystals®. However, high-energy input, lengthy operational units,
and the potential to introduce contamination from the use of grinding media are draw-
backs of this technology. For instance, high pressures of up to 1700 bar with 50–100 cycles
of homogenisation are often required to achieve a desired particle size distribution and
size [3,47]. Furthermore, the milling time varies from hours to days depending on the
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properties of the API, milling media, and extent of required particle size reduction [46,48].
Since contamination from grinding media may lead to unexpected side-effects and/or
toxicities, the top-down production method is not a suitable option for the preparation of
parenterally administered NC [49,50].
2.1.1. HPH (IDD-P®, DissoCubes®, and Nanopure®)
During the process of HPH, API-loaded suspensions are introduced into a high-
pressure homogeniser and forced through a narrow orifice in sudden bursts under high
pressure. Owing to this, cavitation, high-shear forces, and particle collisions result in
fracture of API particles. Generally, the HPH method occurs via the following steps: of (i)
crude API powder is dispersed in pure solution or in a solution containing a stabiliser, (ii)
a reduction of particle size occurs by high-speed shearing or homogenization under low
pressure, (iii) HPH is used to achieve the target particle size and size distribution.
Based on the instrumentation and solutions used, HPH processes can be sub-divided
into three patented technologies, including microfluidics for IDD-P® technology, piston
gap homogenisation for DissoCubes® in aqueous media, and Nanopure® for non-aqueous
media. Nonetheless, attainment of formulation optimization requires an investigation into
the effect of various formulation and process parameters.
2.1.2. MM (NanoCrystals®)
In this technique, NC are obtained by subjecting API to a media-milling process.
The media mill consists of a milling chamber, milling shaft, and recirculation chamber [16].
The generation of high energy and shear forces as a result of milling media and API
collisions provide the requisite energy to disintegrate microparticulate drugs into nano-
sized particles. The milling media may be glass, zirconium oxide, or highly cross-linked
polystyrene resin. During this process, the milling chamber is initially charged with milling
media, water or buffer, API and stabiliser. The system is then rotated at a very high shear
rate, and the milling process is performed under controlled temperature conditions in
either batch or recirculation mode. When using the batch mode, dispersions with unimodal
size distribution profiles and mean diameters <200 nm are produced in approximately
30–60 min. The media milling process can successfully process micronized and un-
micronized drug crystals. Following the optimization of formulation and the process
parameters, minimal batch-to-batch variability is observed when evaluating the quality of
resultant dispersion(s).
However, the generation and introduction of milling media residue into the final
product due to media erosion is of major concern. This phenomenon could be problematic
during the production of nanosuspensions intended for chronic administration. However,
the advent of polystyrene resin-based milling media has led to the reduced occurrence of
the aforementioned issue, for which residual polymeric monomers are typically 50 ppb
and the residuals generated during the milling process of not more than (NMT) 0.005 %
w/w of the final product or resulting solid dosage form [50,51].
MM has been used with considerable success to yield NCC containing furosemide and
caffeine, acetamide, urea and nicotinamide as co-formers, carbamazepine, and separately
indomethacin with the co-former saccharin [52]. Initially, the manufacture of micronized
co-crystals of each was performed using liquid assisted grinding (LAG) with methanol,
acetonitrile, or acetone, or using a slurry technique [52]. Subsequently, the resultant co-
crystals were dispersed in a solution containing 0.5 % w/v HPMC and 0.02 % w/v sodium
dodecyl sulphate (SDS) in distilled water and wet-milled using zirconia beads. Wet-milling
was conducted three times at 2000 rpm for 2 min and then 500 rpm for 2 min cycles.
The milling chamber was maintained at –10 ◦C during the process. Lastly, the resulting
suspension and zirconia bead mixture was transferred to a centrifuge filter-mesh chamber
to separate and collect the suspensions at 400 rpm for 1 min [52].
Itraconazole nanosuspensions have also been manufactured using wet-milling with
Tween® 80 dissolved in a 20 mL vial containing 5 mL demineralised water, followed by
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the dispersion of 250 mg itraconazole in this aqueous phase. Different concentrations of
dicarboxylic acid co-formers (maleic, adipic, glutaric, and succinic acid) were dissolved in
the suspension. Zirconium oxide milling pearls (30 g) of 0.5 mm diameter were added to
the suspension. The vials were placed on a roller-mill and grinding performed at 150 rpm
for 60 h after which the nanoparticles were separated from the pearls by sieving [53].
Witika et al. demonstrated the use of (MM) to produce NCC of lamivudine and
zidovudine. The initial step involved the use of solution co-crystallisation to produce
co-crystals. During the second step, NCC were manufactured using a top-down method,
specifically, wet media milling using an in-house modified jigsaw as the milling chamber.
A 115 mg aliquot of the harvested or dried co-crystal was placed in a 1.5 mL stainless steel
milling chamber. The milling liquid comprised of different % w/v TPGS 1000 and SLS
concentrations as defined by experimental design software. Stainless-steel balls were used
as milling media with milling times of 10, 20, or 30 min at a constant milling speed of
65 Hz [54].
2.1.3. Bottom-Up Production Approaches
Bottom-up approaches promote the growth of NC from solution via two crucial
steps viz., nucleation and crystal growth. Nucleation is crucial in the production of small
uniform NC. An increase in nucleation rate results in an increase in the number of nuclei
formed from the supersaturated solution, leading to a decrease in supersaturation and thus
reduced growth for each nucleus [49]. If a large number of nuclei are produced concurrently
during nucleation, a narrow particle size distribution is likely to occur [49]. Therefore,
it is essential to promote rapid and homogeneous nucleation when using a bottom-up
process. In general, the drug solution and an anti-solventare combined using conventional
mixing equipment, e.g., a magnetic stirrer or an agitator blade [55]. Nucleation can be
triggered by mixing with an anti-solvent or removal of solvent [18] or introduction of sonic
waves to induce sonoprecipitation [55,56]. Sonoprecipitation has been used successfully to
develop NCC to produce caffeine-containing co-crystals using a single-solvent approach
by separately adding 60 mg caffeine and 48 mg of 2,4-dihydroxybenzoic acid (DHBA) in
7 mL and 242 mL acetone, respectively. The solutions were rapidly injected into 200 mL
of hexane at approximately 0 ◦C and sonicated for 15 s in a cleaning bath. A two-solvent
approach using the same procedure with 125 mg of caffeine and 99 mg DHBA dissolved
separately in 1 mL chloroform and 600 mL acetone and rapidly injected into 100 mL of
hexane at approximately 0 ◦C was also successful in the production of co-crystals, with
Span® 85 as surfactant stabiliser at a concentration of 5 % w/v in hexane [57].
A phenazopyridine-phthalimide nano-cocrystal suspension was produced by dis-
solving 213 mg phenazopyridine and 147 mg phthalimide in 2 mL of dimethyl sulfoxide
(DMSO) separately, after which the individual solutions were rapidly injected into 50 mL
0.4 % w/v SDS aqueous solution at approximately 2 ◦C using ultrasonic conditions resulting
in the formation of a NCC suspension after 15–30 s [58].
Liu et al. [59] produced NCC using top-down and bottom-up approaches. NCC pro-
duced using a solution approach were obtained by dissolving 311 mg myricetin and 402 mg
nicotinamide separately in 7 mL and 3 mL methanol, respectively [59]. The solutions were
rapidly injected together into a conical flask at 0 ◦C and sonicated for 30 min using an
ultrasonic processor set at a frequency of 40 kHz with a power output of 50 W follow-
ing which the low-temperature control was stopped but ultrasonic agitation maintained.
The resultant precipitate was removed after 10, 20, and 30 min, filtered and dried for 24 h
at 25 ◦C [60].
Witika et al. reported the synthesis of lamivudine and zidovudine NCC using a
bottom-up technique [19,42]. The NCC were manufactured using a pseudo one solvent
cold sonochemical synthesis technique [19,42]. The individual components were dissolved
in methanol and water and injected into a precooled conical flask and sonicated.
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3. Nucleation and Crystal Growth
Supramolecular synthons are defined as structural units within super-molecules which
can be formed and/or assembled by known synthetic operations involving intermolec-
ular interactions. Supramolecular synthons are spatial arrangements of intermolecular
interactions. Therefore, the overall goal of crystal engineering is to recognise and de-
sign synthons that are robust enough to be interchanged between network structures [9].
The Cambridge Structural Database may be used to identify stable hydrogen bonding
motifs with the ambition that the most robust motifs will remain intact across a family of
related structures [61,62].
3.1. Supramolecular Processes in Crystal Growth
Nucleation is a molecular assembly process, where a critical number of molecules are
needed to achieve a phase change from the liquid melt or solution to form a crystalline solid.
The driving force for achieving the critical point of molecular assembly is linked to the
free energy of the process [6]. For solution-based crystallisation, which is predominantly
used in processing API, the free energy required is linked to the solubility behaviour of the
material in a specific solvent. The magnitude of the difference in solubility exhibited by the
molecules that are crystallising from a completely solubilised state at a specified composi-
tion and temperature drives the process. The larger the differential between solubilised
state and the equilibrium state, the greater the supersaturation. The resultant growth of a
crystal is dependent on the solubility behaviour and any competing nucleation, which may
also be taking place because of the degree of supersaturation achieved. It is, therefore, this
phase change process that distinguishes crystallisation from dissolution [63,64].
3.2. Crystal Habit, Morphology, and Growth
Once nucleation has been achieved, crystal growth dominates and is the process,
which leads to the evolution of embryonic crystals into a crystal form of defined size and
shape. The key drivers with regard to the shape of the growing crystal are related to the
crystal lattice of molecular solids and the effects of the choice of solvent and additives on
the process of crystal growth. As such, crystal growth is a layer-by-layer process, with the
evolution of layers being defined by crystal packing of the unit cell. The unit cell, in turn,
describes the critical elements of how a specific molecular species has been assembled in
the crystalline state in three-dimension [6,65].
4. Techniques used in the Physicochemical Characterisations of NCM
The characterization approaches for NCM are a combination of techniques used
to determine crystallinity, particle size, particle size distribution, as well as intra- and
intermolecular interactions. In addition, beneficial characterization of NCM with regard
to chemical composition is often required. Broadly, the characterization of NCM, much
like any other nanometric drug delivery systems, can be classified into in vitro and in vivo
categories [66].
To understand the potential performance of NCM in vivo, physicochemical charac-
terisations need to be carried out, followed by cell-culture studies. The physicochemical
characterisations offer an understanding of how the NCM will perform prior to cell test-
ing [67]. These are often conducted “in-glass”. Cellular testing is less ethically ambiguous,
is easier to control and reproduce, and is less expensive when compared to animal test-
ing [68]. Once a proof of concept for NCM has been demonstrated in vitro, safety and
therapeutic efficacy are then tested in animal models. The results of animal studies play
a fundamental role in decision-making with regard to progression towards clinical trials.
An animal model that reflects the pathophysiology of human disease is invaluable when
predicting therapeutic outcomes in humans [66,69].
A collection of recommendations pertaining to nanomaterial characterization reviewed
a consensus on a large number of nanomaterial properties [67]. A condensed list of
physicochemical parameters for the risk assessment of nanomaterials was compiled based
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on this collection and we concluded that the nanomaterial properties that are listed in at
least half of the 28 sources analysed were [67];
• Specific surface area
• Particle size








In this review, we will use this list to correlate characterization procedures to the
properties on the list.
4.1. Dynamic Light Scattering (DLS)
Dynamic light scattering (DLS) is commonly used for particle size determination and
measures the Brownian motion of particles in suspension by relating velocity, known as the
translational diffusion coefficient, to the size of particles according to the Stokes–Einstein
equation [70,71].
4.1.1. Particles Size (PS)
Particle size (PS) investigations serve as one of the main determining factors of biodis-
tribution and retention of NCM in target tissues. PS is defined as the size of a hypothetical
hard sphere that exhibits the same diffusion characteristics as the NCM being measured.
The result is reported as mean particle size and homogeneity of size distribution. The latter
parameter is expressed as the polydispersity index (PDI), which is a dimensionless param-
eter calculated from cumulative analysis of the DLS-measured intensity autocorrelation
function [71]. A PDI value in the range <0.25 indicates a desirable homogeneity whereas a
PDI value >0.5 indicates heterogeneous particle sizes [72]. While DLS provides a simple
and rapid estimate of particle size, several studies suggest that DLS exhibits inherent
limitations and is relatively poor at analysing multimodal particle size distributions [72,73].
By way of example, when a mixture of 20- and 100-nm nanometre particles are
measured, the signal for the small particles may be lost because the signal intensity of a
spherical particle of radius r is proportional to r [74]. Therefore, the scattering intensity
of small particles tends to be masked by that of larger particles. Microscopy provides
an accurate assessment of the size and shape of a NCM but often requires complicated
sample preparation steps specific to the microscopic technique used [73], which in turn
may change samples and create artefacts such as NCM agglomeration, which is particularly
observed during drying prior to electron microscopy [75]. Furthermore, due to the limited
throughput capability, it is difficult to obtain an accurate particle size distribution [74], and
the underlying principle is that the sample status in each method is not the same.
4.1.2. Surface Charge
Surface charges, expressed as the Zeta Potential (ZP), critically influences the interac-
tion of NCM with the dispersion media [72]. The ZP is commonly measured using Laser
Doppler Electrophoresis (LDE), which evaluates the electrophoretic mobility of suspended
NCM in a dispersion medium. It is a measure of the energy potential at the boundary of
the outer layer. It is generally accepted that NCM that possess a ZP more positive than +30
mV or more negative than −30 mV exhibit colloidal stability that is maintained by repul-
sion due to electrostatics. Much like with PS measurements, heterogenous samples have
misleading ZP measurements due to the ZP of larger particles dominating the scattering
signal to the detriment of smaller particles [76]. The measurement of the ZP is, in part,
dependent on the ionic strength and valency in an NCM dispersion. High ionic strength
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and valency ions compress the electric double layer, resulting in a reduced ZP. The pH
also has a significant influence on ZP and in alkaline suspensions, the NCM acquire a
negative charge and vice versa. Therefore, ZP should be reported with a corresponding pH
at which the measurement was taken [70]. Additionally, it is recommended that informa-
tion of the suspension be precisely described when reporting the ZP, including the ionic
strength, composition of the dispersion medium, and pH [77,78]. However, the ZP is of
little consequence if the NCM is stored as a solid intended to be redispersed prior to use.
4.2. Thermal Analysis
NCM exhibit many unique properties, which are often superior to those of coarse-
grained materials. Consequently, NCM offer significant potential for use in a variety of
pharmaceutical applications. Solidification of nanosuspensions of NCM has been identified
as a tool to increase patient acceptance/adherence and long-term stability [79].
Due to a high-volume fraction of grain boundaries, NCM have the intrinsic shortcom-
ing of poor thermal stability that significantly limits their use. To aid in understanding this
drawback, thermal stability has become a significant aspect in the field of pharmaceutical
NCM research [80]. It is therefore of utmost importance to conduct thermal analyses on
NCM to determine their suitability in potential secondary or downstream pharmaceuti-
cal applications.
4.2.1. Thermal Gravimetric Analysis (TGA)
TGA is one of the oldest thermal analytical procedures and has been used extensively
in the study of material science. The technique monitors changes in sample weight, usually
nitrogen, as a function of temperature. TGA can be used to facilitate the assessment of
processing temperatures of thermally based secondary manufacturing processes such
as hot-melt extrusion while also finding utility in determining the presence of residual
solvents or moisture. When used as a pre-formulation tool for hot-melt extrusion, TGA is
used to determine the thermal stability of the polymers and nanocrystalline API. It allows
for the determination of a range of operating temperatures in hot-melt extrusion. This
is done in order to avert thermal degradation that may occur during the manufacturing
process. TGA can also be used to determine the moisture or residual solvent contents as
well as the presence of a solvate in NCM, especially in the instances where a crystallization
step was part of the synthetic process of a given NCM.
4.2.2. Differential Scanning Calorimetry (DSC)
DSC is a thermal analytical technique that provides qualitative and quantitative
information as a function of time and temperature in respect of thermal changes in materials
that involve endothermic or exothermic processes, or changes in heat capacity [81].
DSC is used for the determination of melting point, glass transition temperature, and
purity of samples. When applied to NCM products, it is useful in determining changes
in crystallinity, glass transition of stabilizing material, and the presence of more than one
polymorphic form of the API. This is especially important for API that occurs in different
polymorphic forms. Moreover, some top-down techniques like HPH can lead to a batch
with an amorphous fraction. This, in turn, could lead to a significant increase in saturation
solubility. The DSC of a pure drug, a physical mixture of drug and excipients (stabilizer),
and the final formulation, which may be in dried form, is routinely done as pre-formulation
and post-formulation quality tests [82].
Kocbek et al. prepared Pluronic® 68 stabilized ibuprofen nanosuspensions. The study
results indicated the formation of a eutectic mixture of the drug and Pluronic® 68. In
this case, DSC revealed a lower temperature melting peak representing the melting of the
eutectic system, and a second peak representing the melting of the excess ibuprofen. Based
on the position of the second peak, it was estimated that ibuprofen was in excess after
eutectic formation [83].
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Similarly, DSC was used to investigate the changes in the crystallinity of itraconazole
(ITR) after the nanoprecipitation and drying processes or possible interactions between
the API and excipients [84]. The results obtained indicated a small change in melting
temperature of ITR, which were attributable to the reduction in PS and were deemed to not
have been a consequence of CPP. The results also showed the presence of an amorphous
component of ITR and confirmed the presence of both crystalline and amorphous ITR [84].
Although DSC cannot be used to establish the chemical nature of a sample being
tested, the results can be useful for determining whether samples exhibit different thermal
properties and can therefore distinguish differences relating to material identity, specific
solid-state forms, and/or purity [85].
4.3. X-Ray Techniques
X-ray diffraction (XRD) is one of the most widely used techniques for the character-
ization of NCM. Ideally, crystalline structure, phase behaviour, lattice parameters, and
crystallite grain size are derived from XRD [86]. Crystallite grain size is determined using
the Scherrer equation [87]. It utilizes the diffractogram of the sample by analysing the
broadening of the peaks of the highest intensity. XRD has the advantage of resulting in
volume-averaged values while being statistically representative. Despite its applicability,
XRD is often replaced in use by single-crystal X-ray diffraction (ScXRD) as the latter is
a more definitive technique for determining three-dimensional crystal lattice structures.
ScXRD provides an accurate representation of atomic coordinates and thermal parameters.
These are obtained by using parameters such as molecular geometry and intermolecular
distances [88]. ScXRD does have a major disadvantage in that it requires the accessibility
of a single crystal. Unfortunately, in many instances, polycrystallites are formed, especially
when using the top-down methods. In such cases, powder X-ray diffraction (PXRD) is the
obvious alternative to ScXRD [88].
X-ray photon spectroscopy (XPS) capitalizes on the photoelectric effect [89]. In XPS,
following adsorption of incident photons from an X-ray source, core electrons are emitted
from a sample and the kinetic energy determined by conservation of energy. As a result of
inelastic processes from scattering deep in the bulk, only surface electrons escape without
energy loss. Identification of specific elements is accomplished on the basis that each
element has a characteristic set of binding energies. The concentration of the element
directly correlates to the number of photoelectrons and as such, after background removal,
peak areas can be used as a means to quantify specific elements [89].
4.3.1. Powder X-ray Diffraction (PXRD)
PXRD is a non-destructive analytical technique used for the measurement of crystalline
and non-crystalline materials. It is utilized to collect structural data at the anatomic
level to understand phase transitions, determine the degree of crystallinity, and identify
polymorphic and solvatomorphic phases [90,91]. It is an essential tool in pharmaceutical
research as it can be applied to polycrystalline materials in both solid and liquid forms. It
has application in all stages of drug development, production, and quality control testing
of API, excipients, and final products [90,91]. It is an easy-to-use technique, yields reliable
and reproducible results and is relatively inexpensive. Moreover, it is highly sensitive and
has applications in both qualitative and quantitative analyses [90].
PXRD is more difficult to use to determine the crystal morphology or habit of an
API and excipients, and to investigate crystal morphology changes while these substances
maintain crystallinity [92]. Peak broadening for particles below 3 nm in size coupled with
non-suitability for amorphous materials are the main drawbacks of this technique [86].
In research conducted by Upadhyay et al., the PS of magnetite nanoparticles were deter-
mined using X-ray line broadening. The broadening of XRD peaks was mainly caused by
particle/crystallite size and lattice strains other than instrumental broadening [93].
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Similarly, Li et al. used XRD and noticed that after preparing copper telluride nanos-
tructures with different shapes (i.e., cubes, plates, and rods), the relative intensities between
the different XRD peaks varied in relation to the particle shape [94].
The XRD-derived size is often larger than magnetic size. This is due to smaller domains
being present in a particle where all moments are aligned in the same direction, even if the
particle is a single domain. Consequently, the use of microscopy is often preferred for size
determination over XRD [95].
4.3.2. Small Angle X-ray Scattering (SAXS)
For nanomaterials, SAXS is usually the best choice because below a certain particle
size, PXRD is not sufficiently sensitive and the X-rays are scattered in an amorphous halo.
SAXS can be used to elucidate the PS, PDI, and morphology [86]. With regards to PS,
more statistically reliable results are obtained with SAXS when compared to transmission
electron microscopy (TEM). SAXS has been used successfully to study the structural
changes of platinum (Pt) nanoparticles (NP) with changes in temperature [96]. The size
obtained by XRD was different from the corresponding SAXS value at certain temperatures.
This is because XRD is susceptible to the size of the long-range order region while SAXS
is susceptible to the size of the fluctuation region of electronic density [86]. In these
experiments, it was observed that the PS obtained with SAXS were slightly larger than
those obtained using TEM. The reason is that Pt NP were coated with polyvinyl pyrrolidone
(PVP) and the scattering intensity due to the PVP coating could not be easily removed [96].
Cipolla et al. used to SAXS to determine the PS, shape, and asymmetry of liposomes
loaded with NC [97,98]. As part of the study outcomes, SAXS was identified as a useful
and versatile technique to study the solid state of NC loaded in liposomes and dispersions,
as well as to study the behaviour of drug NC in dispersion as a variable of temperature
and pH [98].
SAXS has also found use in the solid-state characterization of doxorubicin sulphate
nanocrystal loaded liposomal dispersions [99,100].
It has to be noted that SAXS is a low-resolution technique and in certain cases, further
studies by XRD and/or electron diffraction techniques are indispensable for the characteri-
zation of NCM.
4.3.3. X-Ray Photon Spectroscopy (XPS)
Due to its ability to determine surface elemental composition and by virtue of being
non-destructive, XPS has become a key characterization technique for NCM [101]. It can
be utilized to provide detailed and qualitative information on chemical elements present
on the surface of materials. This is particularly useful for NCM stabilized by polymers
and/or surfactants. [102]. Recent advances utilizing special sample cells permits the use
of liquid samples and consequently broadens the application of XPS [103], specifically for
dispersed NCM.
Due to the nature of NCM, XPS has taken on more significance in the advancement
of pharmaceutical nanotechnological applications by being capable of detecting the pres-
ence and determining the relative concentrations of elements while also determining the
average thickness of surface coatings in NCM. As such, it is a useful technique for analy-
sis of potential adulteration or impurities arising during nanomaterial synthesis and/or
handling [89].
Through XPS, Qiu et al. conducted an investigation into the difference in reduction
behaviour between nanocrystalline and microcrystalline ceria after Ar+ bombardment or
X-ray irradiation. Despite identical experimental conditions, viz. pellets compacted by
uniaxial pressure of 10 MPa and XPS data being recorded before and after bombardment
experiments, it was observed that the reduction levels of Ce4+ to Ce3+ were lower in
nanocrystalline than microcrystalline ceria [104].
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Chow et al. used XPS to ascertain drug encapsulation and demonstrated that most of
the drug was entrapped within the cores of NPs, and that the particle composition of the
surface was mainly the adsorbed co-stabilizer and polyethylene glycol (PEG) block [105].
Similarly, Dong et al. used XPS to prove the predominant presence of the PEG shell on
the surface of paclitaxel loaded methoxy poly(ethylene glycol)-poly(lactide) (mPEG-PLA)
NP [106].
In a study to analyze the external surface of a novel controlled release formulation
for the anticancer drug paclitaxel (Taxol®) loaded in PLGA nanoparticles and stabilized
by α-tocopheryl polyethylene glycol succinate 1000 using XPS, it is determined that the
outermost layer was composed by a majority of TPGS 1000 molecules [107].
4.4. Vibrational Spectroscopy
4.4.1. Fourier Transform Infrared (FTIR) Spectroscopy
FTIR spectroscopy is used for the physical and chemical characterization of powder
mixtures in the solid state by evaluating functional groups, identifying bond formation,
and comparing bond formation [108,109]. It is a fundamental approach for the study of
API-excipient interactions since it permits rapid and simple elucidation of chemical and
structural attributes of organic materials as it is sensitive to molecular vibrations that are
specific for specific functional groups [108]. Molecular vibrations are categorized based
on the energy related to the functional groups within molecules over the 650–4000 cm−1
wavenumber range [109].
FTIR is mostly used to identify the purity of drug compounds in the crystal, to as-
certain the polymorph in the NCM, and some cases are used to determine whether a
solvate form of the NCM is present. FTIR can be of specific use in the determination of
polymorphic changes during the nanosizing process. For instance, during HPH, piroxicam
demonstrated to undergo polymorphic transformation [110]. The piroxicam nanocrystals
were stabilized using poloxamer 188. FTIR was used in conjunction with other charac-
terization techniques and confirmed that the crystalline form I of piroxicam made up the
majority of the unprocessed piroxicam. A change of colour from white to yellow following
HPH indicated a polymorphic conversion from form I to form III and the monohydrate.
Confirmation using XRD, FTIR, and DSC confirmed that NC were a mixture of form III
and the monohydrate [110].
Lamivudine-zidovudine NCC were synthesized with or without stabilizer [19,111].
The NCC formulation was stabilized with different stabilizers including SDS, TPGS 1000,
Tween® 80, and Span® 80. The FTIR spectrum of the NCC was compared to those of
the individual drug compounds to verify the absence of chemical interactions. The FTIR
spectrum of the NCC revealed the presence of a monohydrate with the presence of a water
peak without any peaks corresponding to the API [19,111].
FTIR was used to identify polymorphic changes in wet-milling using an HPH for
an experimental anti-cancer compound, SN 30191. The process-induced transformations
were studied as a function of time and pressure using infrared spectroscopy, and it was
determined that conversion from form II to form I was pressure-dependent [112].
4.4.2. Raman Spectroscopy (RS)
RS is a versatile analytical technique that can be used in drug and formulation de-
velopment, process control, as well as post-sale analyses [88]. Multivariate data analysis
techniques are valuable for opening spectra to interpretation, allowing quantification of
compounds, and simplification of large spectral data sets. In the pharmaceutical industry,
multivariate techniques, such as partial least squares (PLS) analysis has permitted com-
pounds or properties of compounds to be quantified. API quantification and the ability to
determine interactions between API and excipients are examples of this [88].
RS can be used as a tool to identify the phases and phase transitions of various NCM,
determine which regions of a nanomaterial are amorphous or crystalline [113–115], whether
there are any defects present in the nanomaterial, determine the size (diameter, lateral
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dimensions, etc.) of various types of nanomaterials [116,117], whether the nanomaterial is
homogenous or whether a dispersion of nanoparticles is uniform in size, determine the
shape of nanomaterials (rod, spherical, etc.), and differentiate between different allotropes
of the same material [118].
Spironolactone NC were synthesized with different stabilizers including poloxamers
407 and 188, hydroxypropyl methylcellulose (HPMC), and sodium deoxycholate. Pre-
formulation and post-formulation experiments using RS to compare the drug nanosuspen-
sions and raw materials were used. Peak shifts were not observed in spironolactone NC
stabilised with poloxamer 188, HPMC, and sodium deoxycholate. However, the Raman
spectra revealed API peak disappearance with poloxamer 407 stabilized NC, indicating
that interactions between drug and stabiliser had occurred in that case [119].
A novel bottom-up process to fabricate fenofibrate NCM termed as “controlled crys-
tallization during freeze-drying” (CCDF) was used to synthesize NC. The size of the NC in
this process was influenced by various factors including the freezing rate. To determine the
stage at which solute crystallisation occurred, RS monitoring was used. The in-line Raman
measurements showed that the first two steps, the freezing step, and the crystallization
step are critical steps that determined the final size of the fenofibrate crystals [120].
4.5. Microscopy Techniques
Microscopy imaging is extremely useful when examining the size, shape, and detailed
morphology of particles, and for understanding morphology-related properties of sub-
stances, formulations, and/or dosage forms [121]. The techniques are frequently used in
research and development, especially for solid dosage forms while only a limited number
of examples are referenced here. In the evaluation of pharmaceutical raw materials such as
API and excipients, microscopy images reveal the size, shape, and morphology of parti-
cles, which helps in understanding some processing properties and the pharmaceutical
performance of these materials [122,123]. The impact of different preparation procedures,
such as precipitation or milling methods, on important properties (shape, size, chemical
composition) of the resulting API or excipient particles in NCM can be investigated using
microscopy [124–127].
4.5.1. Scanning Electron Microscopy (SEM)
SEM is an analytical technique used for the characterization of surface morphology of
API and excipients microscopically, in particular, differences in crystal habits and the shape
of the samples [128,129]. SEM does not convey any information in respect of the chemical
structure and/or thermal behaviour of compounds, and is used with other thermal and
spectroscopic methods such as DSC, TGA, and FTIR to identify incompatibilities between
API and excipients [129].
4.5.2. Scanning Electron Microscopy Energy Dispersive X-ray Spectroscopy (SEM-EDX)
Investigation of a sample by SEM does not only produce images but may also provide
specific information in respect of the chemical composition of a sample at specific locations
in the sample. Energy-dispersive X-ray spectrometry (EDX) is based on the generation of
X-rays following the interaction of an electron beam with the atoms in a sample. SEM-EDX
has potential applications in NC and NCC use particularly in determining contamination
that could arise from milling media. EDX has been successfully used for this application.
EDX can also be used to surmise the overall presence of coating agents through determining
the presence of coating agent-specific atoms or by observing an increase or reduction in
atomic % of pure drug elemental components. EDX was specifically used for both of these
applications for the determination of the presence of TPGS 1000 and SDS in NC prepared
using the bottom-up method, and the presence of chromium and iron contamination from
the steel media milling media during the top-down manufacture of lamivudine-zidovudine
NCC [42,111].
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4.5.3. Transmission Electron Microscopy (TEM)
Conventional transmission electron microscopes are electron-optical instruments anal-
ogous to light microscopes [130]. The main difference being that in TEM, the illumination
of the specimen is by an electron beam as opposed to light. An increase in acceleration
voltage of the electrons directly results in an increase in resolution. However, a reduction
in contrast results from increasing acceleration voltage as a consequence of the scattering
of the electrons being decreased at higher velocity [131].
TEM is particularly useful for the study of colloidal and nanostructured drug delivery
systems including NCM [88,132]. Much like SEM, TEM is more useful in determining
surface morphology, differences in crystal habit, and determining particle shape. TEM
is widely the most applied method for evaluation, is used in many characterisation ap-
proaches, and is considered the gold standard for PS determination.
4.6. Quantitative Techniques
4.6.1. (Ultra) High-Performance Liquid Chromatography ((U)HPLC)
During different stages of pharmaceutical development, including synthesis and
isolation of API, dosage form development, and pharmacological testing, gas or liquid
chromatographic methods of analysis are used for quantitative and/or qualitative pur-
poses [133].
High-Performance Liquid Chromatography (HPLC) is based on the principles and
theories of gas chromatography and is a rapid and efficient analytical procedure [134,135].
In the broadest sense, chromatographic separations can be classified as normal (NPC) and
reversed-phase (RPC), where the stationary phase is more polar than the mobile phase for
NPC, whereas the converse is true for RPC [136].
RP-HPLC is the method of choice for in vitro analysis of API due to the stability and
reproducibility of stationary phases used for analyses [137]. A large number of aqueous
components in the mobile phase, in addition to the ease of reproducing analytical methods
in different laboratory settings, make RP-HPLC an ideal analytical method for product
development and quality control purposes in the pharmaceutical industry [137].
The use of stationary phases that have a silica-based backbone chemically bonded
to a variety of different organic functional groups, form the basis for separations in RP-
HPLC [138]. Separation is achieved when the sample to be analysed partitions between an
organic modifier used in the mobile phase and the stationary phase or column [139,140].
In general, non-polar compounds are attracted to hydrophobic stationary phases and
polar compounds preferentially partition into polar mobile phase components [139]. The
specificity and selectivity of an analytical method is the consequence of interaction(s)
between analyte(s) and binding sites of the stationary phase and partitioning in the mobile
phase [141]. Silica-based columns with C3, C4, C8, or C18 alkyl chains bonded to the
backbone are the commonly used non-polar stationary phases in RP-HPLC. Silica-based
phases are compatible, do not swell in water, and some organic solvents are, therefore,
suitable for use with mobile phases comprised of these solvents [139,141,142].
The mobile phase in RP-HPLC is usually water or a buffered solution with an organic
modifier such as methanol or acetonitrile added to the composition in order to reduce
the polarity of the mobile phase, thereby facilitating the achievement of appropriate re-
tention characteristics for the compounds of interest [138]. Other factors that affect the
retention time of analytes include temperature, pH of the buffer and/or mobile phase,
stationary phase properties, polarity of the mobile phase, flow rate, and mobile phase
composition [139,140].
4.6.2. Ultraviolet-Visible Spectrophotometry (UV-Vis Spec)
Spectroscopy is a branch of science which deals with the study of electromagnetic
radiation and its interaction with matter. The UV-visible spectrophotometry specifically is
one of the most often used analytical techniques in the pharmaceutical industry [143,144].
The technique is used to evaluate the concentration of a given organic or biological com-
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pound [145,146]. This process is achieved using UV or visible radiations which are absorbed
by a substance in solution [143–145]. The ratio or function of the ratio of the intensity of two
beams of light in the UV-vis region is measured by instruments known as UV spectropho-
tometers [144]. Absorption of radiation of a specific wavelength, λ, is an indication of the
presence of one or more chromophores [147]. A chromophore is a molecular group that has
a pi, π, bond which when inserted into a saturated hydrocarbon, produces a compound
with absorption between 185 nm and 1000 nm [148]. Temperature and pH may also cause
changes in both the intensity and the λ of the absorbance maxima [149,150].
Analysis of compounds using spectroscopy is governed by the Beer–Lambert law [144].
Beer’s law states that the intensity of a beam of parallel monochromatic radiation decreases
exponentially with the number of absorbing molecules [144,151–153]. Thus, according to
Beer, the concentration of a compound is proportional to the absorbance produced [144,150].
Lambert’s law states that the intensity of a beam of parallel monochromatic radiation
decreases exponentially as it passes through a medium of homogenous thickness [152,154].
As both laws deal with the intensity of monochromatic radiation, a combination of the two
laws has been used to yield the Beer–Lambert law [144,151–154].
Different NCM manufacturing methods and conditions have an influence on the solid
state form while environmental conditions affect the thermodynamic stability of the poly-
morphic form [155]. PXRD, DSC, SEM, FTIR, and RS are the most commonly used methods
to establish and monitor the solid-state forms of NCM. The use of microscopy techniques
is the mainstay of PS, particle shape, and morphology determination. A summary of
techniques and their applications is depicted in Table 1.
Table 1. Characterizations associated with NCM (Adapted from [86]).
Entity to Be Characterized Techniques *
Size and morphology DLS, SEM, TEM
Surface charge ZP
Surface chemical analysis XPS, EDX
Crystal structure SAXS, PXRD, DSC
Growth kinetics SAXS, NMR, TEM, cryo-TEM, liquid-TEM





Dispersion of NCM in matrices/supports TEM, SEM
Dissolution Testing (U)HPLC, UV
* Physical state of samples: DLS, ZP, TEM, UV-Vis, NMR, and HPLC; liquid state. All other techniques; solid state.
5. Applications of Characterization Techniques on Prediction of NCM Performance
5.1. Prediction of Physical and Chemical Stability of NCM
The success of API delivery to target tissues is largely dependent on the maintenance
of stability by the NCM in systemic circulation. The fate of NCM, in vivo, is in part
determined by the ability to retain size and payload external to target tissues and to release
API to the cells at predetermined rates in appropriate quantities. Ideally, a nanometric
drug carrier must remain stable by resisting aggregation or degradation while maintaining
API concentrations in the blood until it reaches the target site(s). Altered biodistribution
as well as premature drug release can occur as a result of NCM instability, subsequently
compromising the performance and efficacy of the delivery system. As such, it is of
utmost importance to evaluate NCM with regards to estimating the success of the drug
delivery system.
It is important to conduct a series of in vitro tests to investigate the stability of NCM
in different biologically relevant media. It is ultimately desirable to conduct investigations
into the stability of NCM in vivo since these techniques provide reasonable assessments
and prediction of the likely stability of the formulation in physiological environments.
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5.1.1. Suspension Stability
The main role of stabilizers in NCM synthesis is to prevent the growth of crystals
resulting in micro or macroparticles. However, most stabilizers may offer “stealth” prop-
erties, enhance permeation, prevent efflux, enhance cell-targeting, or prevent clearance.
By careful formulation, the dissolution and stability can be enhanced while also improving
permeation. Consequently performance may be altered by the selection of stabilizers as
part of the critical formulation parameters (CFP) [156].
The majority of stabilizing agents are amphiphilic moieties that have the ability to
adsorb to the surfaces of newly formed drug particles by utilizing hydrophilic-hydrophobic
interactions. This results in an enhancement in the wetting of NC or NCC [155]. In its most
classical form, the DLVO theory describes nanoparticle stabilization based on steric and/or
electrostatic interactions. Steric stabilization, by use of polymers or non-ionic surfactants,
has been more commonly utilized, and has an added facet of being temperature sensitive.
Conversely, electrostatic stabilization is achieved with ionic polymers or surfactants. In sys-
tems where stabilization is achieved only by electrostatic forces, the ZP should be higher
than |30| mV. As previously stated, this value is vulnerable to changes in pH, the presence
of ionic species, and changes in hydration (drying) [155].
The physical stability of NCM is usually predicted in the suspension state by the value
of the ZP [76]. The use of ZP as a predictor of stability has been shown to be applicable
in nano-formulations containing nevirapine [157], efavirenz [158], and curcumin [105].
More specifically, NCM nanosuspensions of miconazole [159], indomethacin [160], and
ascorbyl palmitate [161] exhibited ZP-dependent stability.
5.1.2. Phase Behaviour
For crystal cell units, it is important to confirm that the API exists, and in the case of
NCC, co-former exist as a co-crystal by non-ionic interaction using appropriate analytical
techniques [162]. Furthermore, the extent of polymorphism must be considered when
determining the stability of a system and attempting to predict API release from that system.
The most frequently used techniques for investigating the phase behavior of NCM
include the use of DSC, TGA, PXRD, and ScXRD. By investigating the thermal behavior
and crystallinity of such systems, valuable complementary information can be generated
for the characterization and quality control of NCM formulations and technologies [163].
Modulated temperature DSC (MTDSC) is sensitive and has a high separation capac-
ity with overlapping thermal events as quasi-static material properties, and frequency
dependency of thermal events are monitored, whereas TGA measures sample mass dur-
ing the heating process and is convenient for determining the presence of solvates and
hydrates [163].
5.1.3. Determination of Critical Aggregation or Micelle Concentration
The critical micelle concentration (CMC) can be used as a measure of the stability of
self-assembling NC or NCC systems including polymeric or surfactant stabilized NCM
systems. The CMC is defined as the concentration at which self-assembled particles
may form. This is a quantitative measure of the physical stability of NCM in solution.
A relatively low CMC is indicative of more stable NCM systems than those in which a high
CMC is likely. In other words, NCM prepared using stabilizers with a low CMC are more
likely to maintain state as a consequence of dilution in the blood [164–168].
5.1.4. Chemical Degradation Analysis
The most standard approach to monitor and/or detect chemical degradation is anal-
ysis using (U)HPLC. Impurities or degradation products often present as new peaks;
however, recognition of additional products often requires the use of techniques such
as liquid chromatography-mass spectrometry (LC-MS). Degradation of molecules can
be induced using harsh processing conditions, and exact knowledge of the chemistry of
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unwanted products is crucial in order to recognize and avoid potentially problematic
process steps [163].
Vibrational spectroscopic methods may also be used to determine whether a chemical
change has taken place during the process of manufacture and storage. The disappearance
of peaks associated with key frequencies of the API could be an indication of degrada-
tion. FTIR and RS have been used to ascertain that NCM formulated for the delivery of
lamivudine-zidovudine [19,42,111], tadalafil [169], and diclofenac [170] had not undergone
chemical degradation or chemically interacted with the stabilizers.
While less commonly used for the purposes of determination chemical degradation,
SEM-EDX may offer valuable information regarding the state of the NCM within a bulk.
The technique was effectively used to determine whether chemical degradation had oc-
curred by revealing the disappearance of elemental peaks of the appearance of new ones.
In addition, the percentage of abundance was equally used as a determinant of chemical
degradation for the NCM [42].
5.2. In Vitro Dissolution and Kinetics of Drug Release
When NCM is used for delivery of API, the release of the API is evaluated over
time in order to determine the availability of API for absorption and ultimately at target
sites thereby influencing therapeutic outcomes [72]. Three possible mechanisms of release
from NCM can be envisaged viz., desorption of adsorbed API (A), API diffusion from a
polymer/surfactant matrix (B), and/or release following polymer/surfactant erosion (C)
as depicted in Figure 1.
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membrane diffusion method typically makes use of large volumes of dissolution media. 
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In the case of matrix-type polymer/surfactant NCM in which the crystalline API is
uniformly distributed or embed ed in the matrix, drug release would be predominantly
controlled by diffusion through the matrix and/or erosion of the matrix. Depending on
the API and matrix physico hemical properties, ither one of these mechanisms can be the
dominant one. If diffusion occurs more rapidly than matrix/surfactant degradation, diffu-
sion is likely to be the main mechanism of release. In many instances, an initial rapid initial
release is noticed and attributable to the crystalline material fr ction adsorbed or weakly
bound to the surface(s) or that is not entirely mbedded in the system (Figure 1A) [171].
API release from NCM is investigated in a number of ways. These are by dialysis
membrane diffusion, embrane-less diffusion, s mpling and separation, or the use of an
in situ analytical technique [172]. When ng the sampling and separation t chnique,
API release is determi ed by separating the relea ed API from the sample by filtration,
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centrifugation, or centrifugal filtration, and subsequent quantification using an appropriate
analytical method such as (U)HPLC or UV spectroscopy.
The NCM are augmented with fresh release medium, preferably simulated bodily
fluids and resuspended and incubated further until the next sampling interval. Despite
this method having the capability of being performed with a small sample size and simple
analytical equipment, several drawbacks exist: the separation methods is slow, tedious,
and inefficient, making it inappropriate for studying rapid/immediate release NCM. In
addition, the force of centrifugation or shear stress during filtration required for NCM
separation tends to increase with a reduction in NCM PS. This can ultimately alter the
release kinetics of the API. The main advantage of the dialysis membrane diffusion tech-
nique is that he diffusion of the NCM is continuous across the dialysis membrane and
not subject to destructive separation processes, making sample acquisition simple and
rapid [163,173,174].
The use of dialysis membranes may attenuate API release as it is a diffusion barrier
that may behave as an adsorptive surface. Thus, this approach should be conducted with
control experiments in which free API is used to assess membrane effects. The dialysis
membrane diffusion method typically makes use of large volumes of dissolution media.
While large volumes maintain sink conditions for release, API analysis may be hindered
due to the low concentrations to be tested. An in situ analytical technique is useful for
studying NCM, which are prepared almost exclusively of an API. This technique is used to
analyse the properties of NCM in situ to indirectly determine the quantity of API released.
Various analytical techniques, including electrochemical analysis, solution calorimetry, or
turbidometric and the light scattering techniques have been used for this purpose [172].
These approaches do not need separation of NCM and enable real-time assessment of the
release kinetics of API.
While the aforementioned characterizations may be generally applicable, it may not
always be applicable to use all of them. The role of PS, PDI, ZP, and polymorphism on
NCM performance with regards to processability, content uniformity, and stability of a
drug product is recognizable. The possible effect of PS and polymorphism on solubility,
dissolution, and bioavailability parameters being strictly related to each other is one of the
primary concerns. Definitions of specifications are required particularly when the product
performance is affected by PS and polymorphism. We provide an appropriate decision
tree in Figure 2, that is closely adapted to that in the ICH Q6A guidelines [175], on what
characterization is required and to which performance parameter it relates.
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6. Conclusions
NCM are non-toxic crystalline carriers composed almost entirely of API and very
little excipients.
Unlike other nanoparticle technologies such as solid lipid nanoparticles (SLN), nano
lipid carriers (NLC), and nanocapsules, NCM are suitable for the delivery of hydrophilic
and hydrophobic compounds with very high efficiency. NCM are also relatively easy
to prepare and synthesize when compared to other nanoparticle technologies such as
liposomes and nanocapsules that require multiple steps and use of organic solvents. NCM
have the added advantage of exhibiting better stability than other nanoparticles due to
the crystalline state of the particles. In addition, NCM formulations prevent the accumu-
lation of the payload in cells and tissues of healthy organs and often exhibit improved
bioavailability for some API. The suitability of the carriers has been proven since they are
already on the market (Rapamune® and Emend®). NCM fulfil the key prerequisites for
the introduction of the technology to the clinic trial phases and the market, that is, they
are in line with regulatory requirements and provide the possibility of qualified industrial
large-scale production. Furthermore, NCM exhibit flexibility in terms of the route of ad-
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ministration and have been used for oral, parenteral, ophthalmic, and topical delivery of a
variety of compounds.
The characterization of NCM delivery systems is an area that requires the formulation
development and production of a products of high quality. Ideally, NCM should be in the
nano range with a PDI < 0.500, determined using DLS and Photon Correlation Spectroscopy
(PCS) in combination with Laser Diffraction (LD). However, PCS and DLS cannot be used
to characterize the shape, surface morphology, and elemental composition of NCM and
additional analytical tools are required. Therefore, TEM, SEM, and EDX should be used
to assess the shape and surface morphology of NCM in the solid-state and dispersions.
The crystalline nature and polymorphic transition of NCM are characterised using DSC,
TGA, PXRD, and FTIR/Raman spectroscopy to investigate potential interactions between
the API and excipients to be used. Laser Doppler Anemometry (LDA) is used to establish
electrophoretic mobility and the ZP of NCM, which should be > +30 mV or < −30 mV
in dispersion.
Other characterisations perhaps not considered the most fundamental but worth addi-
tional exploration include two-dimensional (2D) nuclear magnetic resonance (NMR) tech-
niques such as correlation spectroscopy (COSY), diffusion-ordered spectroscopy (DOSY),
and cross-polarization magic-angle spinning (CPMAS). These are used to generate addi-
tional information in terms of the stability of the nanocarriers in solution and solid-state in
addition to the presence of hydrogen bonding.
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